CONTINUUS Pharmaceuticals Awarded $4.4 M Contract with US FDA

CONTINUUS Pharmaceuticals, Inc. was recently awarded a $4.4 M contract by the US Food and Drug Administration (US FDA).  The purpose of this collaborative work, entitled “Advancement of Integrated Continuous Manufacturing (ICM) Unit Operations,” is to develop a science and risk-approach on how drug quality can be monitored and improved through integrated continuous manufacturing (ICM).  This work may inform future regulatory guidelines that the pharmaceutical industry can leverage when developing such processes.  To achieve this goal, the CONTINUUS team will  develop a fully automated, end-to-end, integrated continuous pilot plant that will be used to test relevant regulatory principles, including real-time release and traceability. The time frame for this project is three years. Read more about it here